德摩膚爽乳膏

国家: 台湾

语言: 中文

来源: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

有效成分:

MOMETASONE FUROATE

可用日期:

百德健有限公司 臺北市中山區民生東路一段58號11樓 (28843592)

ATC代码:

D07AC13

药物剂型:

乳膏劑

组成:

MOMETASONE FUROATE (6804002310) MG

每包单位数:

鋁管裝

类:

製　劑

处方类型:

須由醫師處方使用

厂商:

DONGKOO BIO & PHARMA. CO., LTD. 18, JEYAKGONGDAN 2-GIL, HYANGNAM-EUP, HWASEONG-SI, GYEONGGI-DO, KOREA KR

治疗领域:

mometasone

疗效迹象:

對類固醇具有感受性之皮膚病所引起之炎性反應及搔癢之緩解。

產品總結:

註銷日期: 2022/07/11; 註銷理由: 許可證已逾有效期; 有效日期: 2020/11/09; 英文品名: DERMOTASONE cream

授权状态:

已註銷

授权日期:

2005-11-09

资料单张

DERMOTASONE CREAM
【
APPEARANCE
】 White cream
【
COMPOSITION
】
One gram contains :
Mometasone Furoate -------------------------------------1.0mg
【
INDICATION
】
Relief of the inflammatory and pruritic manifestations of
corticosteroid responsive dermatoses.
【
DOSAGE AND ADMINISTRATION
】
1. Apply a thin film of Dermotasone Cream 0.1% to the affected skin
areas once daily.
2. Dermotasone cream 0.1% should not be used with occlusive dressings
unless directed by a physician.
【
CAUTION
】
1. Contra indications
1) Patients who have skin infectious diseases; bacteria (tuberculosis,
syphilis, etc), fungus (candida,
dermatophyte), virus (herpes zoster, herpes simplex, chickenpox,
vaccinia, etc), animal (scabies,
phthiriasis pubis, etc).
2) Patients who have been experienced hypersensitivity for this
medicine’s ingredients.
3) Eczematous external otitis patients who have drum membrane
perforation.
4) Patients who have ulcer, burn more than second degree or chilblain.
5) Perioral dermatitis, general acne, rosacera patients.
6) Patients suffering from perianal and genital pruritis.
7) Baby under the age of 2 years.
2. General cautions.
1) Do not use this medicine for eczema, dermatitis accompanied with
skin infection. But if this medicine must
be used in an unavoidable case, treat the symptoms with antibacterial
agent (systemic administration),
antifungal agent first or consider of combined treatment.
2) Systemic absorption of local corticoids may make adverse HPA axis
suppression, cushing’s syndrome,
hyperglycemia, glucosuria, etc to some patients and the patients
treated under wide ranged body surface
or ODT with local corticoids shall be periodically checked about HPA
axis suppression by plasma cortisol
concentrations, measuring cortisol released from urea or ACTH stimulus
test.
3) If HPA axis is restrained by systemic absorption of local
corticoid, stop using medication, reduce the
frequency of administration, and replace to weak activity corticoid.
Generally, hypothalamic pituitary
adrenal axis functi